Perrigo Company plc (NYSE: PRGO) Stock Competitors & Peer Comparison
See PRGO's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRGO and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRGO | $14.48 | +2.84% | 2B | 5.80 | $2.50 | +8.04% |
| TAK | $18.03 | +0.00% | 57.4B | 12.97 | $1.39 | +3.50% |
| HLN | $10.11 | +0.70% | 44.5B | 18.85 | $0.54 | +1.23% |
| TEVA | $36.44 | -3.14% | 42.4B | 12.43 | $2.93 | N/A |
| ZTS | $77.34 | +3.09% | 32.4B | 11.75 | $6.58 | +2.70% |
| VTRS | $16.34 | -3.26% | 19B | 6.48 | $2.52 | +2.92% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $24.11 | -1.55% | 12B | 22.76 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.18 | +0.16% | 10.1B | 19.97 | $0.61 | +0.69% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
PRGO vs TAK Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TAK has a market cap of 57.4B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TAK trades at $18.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TAK's P/E ratio is 12.97. In terms of profitability, PRGO's ROE is -0.56%, compared to TAK's ROE of +0.02%. Regarding short-term risk, PRGO is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check TAK's competition here
Haleon plc (NYSE: HLN)
PRGO vs HLN Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while HLN trades at $10.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas HLN's P/E ratio is 18.85. In terms of profitability, PRGO's ROE is -0.56%, compared to HLN's ROE of +0.17%. Regarding short-term risk, PRGO is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
PRGO vs TEVA Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TEVA has a market cap of 42.4B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TEVA trades at $36.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TEVA's P/E ratio is 12.43. In terms of profitability, PRGO's ROE is -0.56%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, PRGO is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check TEVA's competition here
Zoetis Inc. (NYSE: ZTS)
PRGO vs ZTS Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ZTS has a market cap of 32.4B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ZTS trades at $77.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ZTS's P/E ratio is 11.75. In terms of profitability, PRGO's ROE is -0.56%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, PRGO is more volatile compared to ZTS. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
PRGO vs VTRS Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while VTRS trades at $16.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas VTRS's P/E ratio is 6.48. In terms of profitability, PRGO's ROE is -0.56%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, PRGO is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
PRGO vs ITCI Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ITCI's P/E ratio is -180.64. In terms of profitability, PRGO's ROE is -0.56%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, PRGO is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
PRGO vs ELAN Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ELAN has a market cap of 12B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ELAN trades at $24.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ELAN's P/E ratio is 22.76. In terms of profitability, PRGO's ROE is -0.56%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, PRGO is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
PRGO vs CTLT Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas CTLT's P/E ratio is -27.84. In terms of profitability, PRGO's ROE is -0.56%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, PRGO is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
PRGO vs RDY Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, RDY has a market cap of 10.1B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while RDY trades at $12.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas RDY's P/E ratio is 19.97. In terms of profitability, PRGO's ROE is -0.56%, compared to RDY's ROE of +0.09%. Regarding short-term risk, PRGO is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
PRGO vs ALKS Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ALKS has a market cap of 8B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ALKS trades at $47.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ALKS's P/E ratio is 49.91. In terms of profitability, PRGO's ROE is -0.56%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, PRGO is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
PRGO vs LNTH Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while LNTH trades at $100.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas LNTH's P/E ratio is 16.94. In terms of profitability, PRGO's ROE is -0.56%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, PRGO is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
PRGO vs AMRX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while AMRX trades at $17.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas AMRX's P/E ratio is 19.49. In terms of profitability, PRGO's ROE is -0.56%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, PRGO is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
PRGO vs INDV Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, INDV has a market cap of 4.4B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while INDV trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas INDV's P/E ratio is 9.55. In terms of profitability, PRGO's ROE is -0.56%, compared to INDV's ROE of -2.16%. Regarding short-term risk, PRGO is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check INDV's competition here
Alvotech (NASDAQ: ALVOW)
PRGO vs ALVOW Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ALVOW has a market cap of 3B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ALVOW trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ALVOW's P/E ratio is 47.36. In terms of profitability, PRGO's ROE is -0.56%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, PRGO is less volatile compared to ALVOW. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check ALVOW's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
PRGO vs RGC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while RGC trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas RGC's P/E ratio is -387.32. In terms of profitability, PRGO's ROE is -0.56%, compared to RGC's ROE of -2.32%. Regarding short-term risk, PRGO is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check RGC's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
PRGO vs SUPN Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while SUPN trades at $43.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas SUPN's P/E ratio is 14.29. In terms of profitability, PRGO's ROE is -0.56%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, PRGO is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check SUPN's competition here
Bausch Health Companies Inc. (NYSE: BHC)
PRGO vs BHC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while BHC trades at $6.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas BHC's P/E ratio is 1.61. In terms of profitability, PRGO's ROE is -0.56%, compared to BHC's ROE of +0.89%. Regarding short-term risk, PRGO is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
PRGO vs DCPH Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas DCPH's P/E ratio is -11.58. In terms of profitability, PRGO's ROE is -0.56%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, PRGO is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
PRGO vs HCM Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, HCM has a market cap of 2.2B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while HCM trades at $12.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas HCM's P/E ratio is 4.64. In terms of profitability, PRGO's ROE is -0.56%, compared to HCM's ROE of +0.01%. Regarding short-term risk, PRGO is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
PRGO vs AVDL Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, PRGO's ROE is -0.56%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, PRGO is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check AVDL's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
PRGO vs TRLV Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TRLV has a market cap of 2B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TRLV trades at $11.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TRLV's P/E ratio is -4.80. In terms of profitability, PRGO's ROE is -0.56%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, PRGO is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check TRLV's competition here
Embecta Corp. (NASDAQ: EMBCV)
PRGO vs EMBCV Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas EMBCV's P/E ratio is N/A. In terms of profitability, PRGO's ROE is -0.56%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, PRGO is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
PRGO vs DVAX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas DVAX's P/E ratio is -41.89. In terms of profitability, PRGO's ROE is -0.56%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, PRGO is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
PRGO vs ALVO Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ALVO has a market cap of 1.7B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ALVO trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ALVO's P/E ratio is -14.56. In terms of profitability, PRGO's ROE is -0.56%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, PRGO is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ALVO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
PRGO vs ANIP Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ANIP trades at $72.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ANIP's P/E ratio is 8.86. In terms of profitability, PRGO's ROE is -0.56%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, PRGO is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ANIP's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
PRGO vs ETON Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ETON has a market cap of 1.6B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ETON trades at $59.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ETON's P/E ratio is 129.96. In terms of profitability, PRGO's ROE is -0.56%, compared to ETON's ROE of +0.40%. Regarding short-term risk, PRGO is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check ETON's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
PRGO vs TARO Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TARO's P/E ratio is 30.05. In terms of profitability, PRGO's ROE is -0.56%, compared to TARO's ROE of +0.03%. Regarding short-term risk, PRGO is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
PRGO vs PAHC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, PAHC has a market cap of 1.5B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while PAHC trades at $37.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas PAHC's P/E ratio is 12.86. In terms of profitability, PRGO's ROE is -0.56%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, PRGO is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check PAHC's competition here
Harrow Health, Inc. (NASDAQ: HROW)
PRGO vs HROW Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while HROW trades at $37.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas HROW's P/E ratio is -37.65. In terms of profitability, PRGO's ROE is -0.56%, compared to HROW's ROE of -1.04%. Regarding short-term risk, PRGO is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check HROW's competition here
Cronos Group Inc. (NASDAQ: CRON)
PRGO vs CRON Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, CRON has a market cap of 1.3B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while CRON trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas CRON's P/E ratio is 32.10. In terms of profitability, PRGO's ROE is -0.56%, compared to CRON's ROE of +0.06%. Regarding short-term risk, PRGO is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
PRGO vs PCRX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while PCRX trades at $25.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas PCRX's P/E ratio is 9.91. In terms of profitability, PRGO's ROE is -0.56%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, PRGO is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check PCRX's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
PRGO vs AMPH Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, AMPH has a market cap of 970.5M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while AMPH trades at $22.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas AMPH's P/E ratio is 7.51. In terms of profitability, PRGO's ROE is -0.56%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, PRGO is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check AMPH's competition here
PetIQ, Inc. (NASDAQ: PETQ)
PRGO vs PETQ Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas PETQ's P/E ratio is 83.73. In terms of profitability, PRGO's ROE is -0.56%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, PRGO is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
PRGO vs COLL Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, COLL has a market cap of 822.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while COLL trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas COLL's P/E ratio is 3.18. In terms of profitability, PRGO's ROE is -0.56%, compared to COLL's ROE of +0.16%. Regarding short-term risk, PRGO is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check COLL's competition here
Glass House Brands Inc (NYSE: GLAS)
PRGO vs GLAS Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, GLAS has a market cap of 768.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while GLAS trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas GLAS's P/E ratio is -17.73. In terms of profitability, PRGO's ROE is -0.56%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, PRGO is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check GLAS's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
PRGO vs IRWD Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, IRWD has a market cap of 698M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas IRWD's P/E ratio is 5.44. In terms of profitability, PRGO's ROE is -0.56%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, PRGO is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
PRGO vs EVO Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, EVO has a market cap of 678.5M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while EVO trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas EVO's P/E ratio is -2.70. In terms of profitability, PRGO's ROE is -0.56%, compared to EVO's ROE of -0.27%. Regarding short-term risk, PRGO is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
PRGO vs AQST Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, AQST has a market cap of 629.8M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while AQST trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas AQST's P/E ratio is -7.72. In terms of profitability, PRGO's ROE is -0.56%, compared to AQST's ROE of +2.44%. Regarding short-term risk, PRGO is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
PRGO vs EOLS Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, EOLS has a market cap of 584.8M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while EOLS trades at $8.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas EOLS's P/E ratio is -28.12. In terms of profitability, PRGO's ROE is -0.56%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, PRGO is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check EOLS's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
PRGO vs BDSI Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas BDSI's P/E ratio is 6.82. In terms of profitability, PRGO's ROE is -0.56%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, PRGO is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
PRGO vs TLRY Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TLRY has a market cap of 513.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TLRY trades at $4.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TLRY's P/E ratio is -4.23. In terms of profitability, PRGO's ROE is -0.56%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, PRGO is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check TLRY's competition here
Kamada Ltd. (NASDAQ: KMDA)
PRGO vs KMDA Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, KMDA has a market cap of 476.6M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while KMDA trades at $8.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas KMDA's P/E ratio is 21.74. In terms of profitability, PRGO's ROE is -0.56%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, PRGO is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
PRGO vs CGC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, CGC has a market cap of 421.9M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while CGC trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas CGC's P/E ratio is -0.60. In terms of profitability, PRGO's ROE is -0.56%, compared to CGC's ROE of -0.33%. Regarding short-term risk, PRGO is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
PRGO vs TKNO Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TKNO has a market cap of 381.7M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TKNO trades at $7.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TKNO's P/E ratio is -22.97. In terms of profitability, PRGO's ROE is -0.56%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, PRGO is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check TKNO's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
PRGO vs EBS Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, EBS has a market cap of 305.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while EBS trades at $5.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas EBS's P/E ratio is 4.11. In terms of profitability, PRGO's ROE is -0.56%, compared to EBS's ROE of -0.36%. Regarding short-term risk, PRGO is more volatile compared to EBS. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check EBS's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
PRGO vs ALIM Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ALIM's P/E ratio is 5.28. In terms of profitability, PRGO's ROE is -0.56%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, PRGO is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
PRGO vs LNDC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas LNDC's P/E ratio is -4.04. In terms of profitability, PRGO's ROE is -0.56%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, PRGO is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
PRGO vs ACB Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ACB has a market cap of 248.4M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ACB trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ACB's P/E ratio is -8.19. In terms of profitability, PRGO's ROE is -0.56%, compared to ACB's ROE of -0.21%. Regarding short-term risk, PRGO is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ACB's competition here
Shineco, Inc. (NASDAQ: TYHT)
PRGO vs TYHT Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TYHT's P/E ratio is -1.61. In terms of profitability, PRGO's ROE is -0.56%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, PRGO is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check TYHT's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
PRGO vs ORGO Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ORGO has a market cap of 223.9M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ORGO trades at $1.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ORGO's P/E ratio is 58.00. In terms of profitability, PRGO's ROE is -0.56%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, PRGO is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ORGO's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
PRGO vs CRDL Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, CRDL has a market cap of 223.6M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while CRDL trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas CRDL's P/E ratio is -7.73. In terms of profitability, PRGO's ROE is -0.56%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, PRGO is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check CRDL's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
PRGO vs SIGA Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, SIGA has a market cap of 219.5M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while SIGA trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas SIGA's P/E ratio is 11.33. In terms of profitability, PRGO's ROE is -0.56%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, PRGO is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check SIGA's competition here
Journey Medical Corporation (NASDAQ: DERM)
PRGO vs DERM Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, DERM has a market cap of 205.6M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while DERM trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas DERM's P/E ratio is -20.19. In terms of profitability, PRGO's ROE is -0.56%, compared to DERM's ROE of -0.20%. Regarding short-term risk, PRGO is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check DERM's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
PRGO vs REPH Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas REPH's P/E ratio is -8.04. In terms of profitability, PRGO's ROE is -0.56%, compared to REPH's ROE of -0.22%. Regarding short-term risk, PRGO is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check REPH's competition here
Organigram Global Inc. (NASDAQ: OGI)
PRGO vs OGI Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, OGI has a market cap of 171M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while OGI trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas OGI's P/E ratio is 2.73. In terms of profitability, PRGO's ROE is -0.56%, compared to OGI's ROE of +0.21%. Regarding short-term risk, PRGO is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
PRGO vs LFCR Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, LFCR has a market cap of 170.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while LFCR trades at $4.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas LFCR's P/E ratio is -4.24. In terms of profitability, PRGO's ROE is -0.56%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, PRGO is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check LFCR's competition here
Theratechnologies Inc. (NASDAQ: THTX)
PRGO vs THTX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas THTX's P/E ratio is -28.83. In terms of profitability, PRGO's ROE is -0.56%, compared to THTX's ROE of +0.17%. Regarding short-term risk, PRGO is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
PRGO vs ASRT Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ASRT's P/E ratio is -7.10. In terms of profitability, PRGO's ROE is -0.56%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, PRGO is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
PRGO vs CPIX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, CPIX has a market cap of 126.8M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while CPIX trades at $8.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas CPIX's P/E ratio is -21.15. In terms of profitability, PRGO's ROE is -0.56%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, PRGO is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check CPIX's competition here
BGM Group Ltd. (NASDAQ: BGM)
PRGO vs BGM Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, BGM has a market cap of 122.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while BGM trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas BGM's P/E ratio is -1.11. In terms of profitability, PRGO's ROE is -0.56%, compared to BGM's ROE of -0.07%. Regarding short-term risk, PRGO is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check BGM's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
PRGO vs SCTL Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas SCTL's P/E ratio is -7.86. In terms of profitability, PRGO's ROE is -0.56%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, PRGO is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
PRGO vs PROC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas PROC's P/E ratio is 1.53. In terms of profitability, PRGO's ROE is -0.56%, compared to PROC's ROE of -2.22%. Regarding short-term risk, PRGO is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
PRGO vs OPTN Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas OPTN's P/E ratio is -4.42. In terms of profitability, PRGO's ROE is -0.56%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, PRGO is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
PRGO vs ZOM Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ZOM's P/E ratio is -1.62. In terms of profitability, PRGO's ROE is -0.56%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, PRGO is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
PRGO vs GRVI Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas GRVI's P/E ratio is 26.05. In terms of profitability, PRGO's ROE is -0.56%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, PRGO is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
PRGO vs ZYBT Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ZYBT has a market cap of 82M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ZYBT trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ZYBT's P/E ratio is -7.86. In terms of profitability, PRGO's ROE is -0.56%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, PRGO is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check ZYBT's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
PRGO vs ZYNE Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, PRGO's ROE is -0.56%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, PRGO is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check ZYNE's competition here
InterCure Ltd. (NASDAQ: INCR)
PRGO vs INCR Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, INCR has a market cap of 68.5M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while INCR trades at $5.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas INCR's P/E ratio is -13.34. In terms of profitability, PRGO's ROE is -0.56%, compared to INCR's ROE of -0.09%. Regarding short-term risk, PRGO is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check INCR's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
PRGO vs SSIC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas SSIC's P/E ratio is 11.93. In terms of profitability, PRGO's ROE is -0.56%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, PRGO is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check SSIC's competition here
Talphera, Inc. (NASDAQ: TLPH)
PRGO vs TLPH Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TLPH has a market cap of 62.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TLPH trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TLPH's P/E ratio is -3.87. In terms of profitability, PRGO's ROE is -0.56%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, PRGO is more volatile compared to TLPH. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check TLPH's competition here
The Valens Company Inc. (NASDAQ: VLNS)
PRGO vs VLNS Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas VLNS's P/E ratio is -1.03. In terms of profitability, PRGO's ROE is -0.56%, compared to VLNS's ROE of N/A. Regarding short-term risk, PRGO is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
PRGO vs DRRX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas DRRX's P/E ratio is -4.44. In terms of profitability, PRGO's ROE is -0.56%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, PRGO is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check DRRX's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
PRGO vs JUPW Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas JUPW's P/E ratio is -2.41. In terms of profitability, PRGO's ROE is -0.56%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, PRGO is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
PRGO vs QLI Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas QLI's P/E ratio is -4.92. In terms of profitability, PRGO's ROE is -0.56%, compared to QLI's ROE of -0.16%. Regarding short-term risk, PRGO is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check QLI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
PRGO vs CPHI Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, CPHI has a market cap of 36.6M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while CPHI trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas CPHI's P/E ratio is -2.10. In terms of profitability, PRGO's ROE is -0.56%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, PRGO is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check CPHI's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
PRGO vs RMTI Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, RMTI has a market cap of 32.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while RMTI trades at $8.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas RMTI's P/E ratio is -6.10. In terms of profitability, PRGO's ROE is -0.56%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, PRGO is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check RMTI's competition here
HEXO Corp. (NASDAQ: HEXO)
PRGO vs HEXO Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas HEXO's P/E ratio is -0.26. In terms of profitability, PRGO's ROE is -0.56%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, PRGO is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check HEXO's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
PRGO vs TXMD Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, TXMD has a market cap of 25.7M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while TXMD trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas TXMD's P/E ratio is 113.09. In terms of profitability, PRGO's ROE is -0.56%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, PRGO is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check TXMD's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
PRGO vs AYTU Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, AYTU has a market cap of 24.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while AYTU trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas AYTU's P/E ratio is -1.17. In terms of profitability, PRGO's ROE is -0.56%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, PRGO is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check AYTU's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
PRGO vs CYTH Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas CYTH's P/E ratio is -0.80. In terms of profitability, PRGO's ROE is -0.56%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, PRGO is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
PRGO vs EVOK Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas EVOK's P/E ratio is -7.97. In terms of profitability, PRGO's ROE is -0.56%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, PRGO is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
PRGO vs OPTH Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, OPTH has a market cap of 15.9M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while OPTH trades at $4.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas OPTH's P/E ratio is -18.08. In terms of profitability, PRGO's ROE is -0.56%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, PRGO is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
PRGO vs ACRX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ACRX's P/E ratio is -0.31. In terms of profitability, PRGO's ROE is -0.56%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, PRGO is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
PRGO vs CABR Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, CABR has a market cap of 12.6M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while CABR trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas CABR's P/E ratio is -2.48. In terms of profitability, PRGO's ROE is -0.56%, compared to CABR's ROE of -3.28%. Regarding short-term risk, PRGO is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
PRGO vs AGRX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas AGRX's P/E ratio is -0.89. In terms of profitability, PRGO's ROE is -0.56%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, PRGO is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
PRGO vs NLTX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas NLTX's P/E ratio is -0.28. In terms of profitability, PRGO's ROE is -0.56%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, PRGO is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
PRGO vs LCI Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas LCI's P/E ratio is -0.04. In terms of profitability, PRGO's ROE is -0.56%, compared to LCI's ROE of +1.66%. Regarding short-term risk, PRGO is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
PRGO vs ADMP Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ADMP's P/E ratio is -0.08. In terms of profitability, PRGO's ROE is -0.56%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, PRGO is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
PRGO vs YCBD Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, YCBD has a market cap of 5.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while YCBD trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas YCBD's P/E ratio is -1.25. In terms of profitability, PRGO's ROE is -0.56%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, PRGO is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
PRGO vs GELS Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, GELS has a market cap of 5.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas GELS's P/E ratio is -1.11. In terms of profitability, PRGO's ROE is -0.56%, compared to GELS's ROE of -0.25%. Regarding short-term risk, PRGO is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
PRGO vs MNK Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas MNK's P/E ratio is -0.44. In terms of profitability, PRGO's ROE is -0.56%, compared to MNK's ROE of -0.36%. Regarding short-term risk, PRGO is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
PRGO vs FLGC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas FLGC's P/E ratio is -0.19. In terms of profitability, PRGO's ROE is -0.56%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, PRGO is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
PRGO vs UPC Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, UPC has a market cap of 3.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while UPC trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas UPC's P/E ratio is -0.62. In terms of profitability, PRGO's ROE is -0.56%, compared to UPC's ROE of -0.03%. Regarding short-term risk, PRGO is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
PRGO vs SBFM Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, SBFM has a market cap of 2.7M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while SBFM trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas SBFM's P/E ratio is -0.19. In terms of profitability, PRGO's ROE is -0.56%, compared to SBFM's ROE of -0.24%. Regarding short-term risk, PRGO is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
PRGO vs PLXP Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas PLXP's P/E ratio is -0.22. In terms of profitability, PRGO's ROE is -0.56%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, PRGO is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check PLXP's competition here
Athenex, Inc. (NASDAQ: ATNX)
PRGO vs ATNX Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas ATNX's P/E ratio is -0.02. In terms of profitability, PRGO's ROE is -0.56%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, PRGO is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for PRGO.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
PRGO vs SNOA Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, SNOA has a market cap of 2.2M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while SNOA trades at $1.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas SNOA's P/E ratio is -1.11. In terms of profitability, PRGO's ROE is -0.56%, compared to SNOA's ROE of -0.46%. Regarding short-term risk, PRGO is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check SNOA's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
PRGO vs SHPH Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, SHPH has a market cap of 2.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while SHPH trades at $3.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas SHPH's P/E ratio is -0.17. In terms of profitability, PRGO's ROE is -0.56%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, PRGO is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check SHPH's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
PRGO vs RDHL Comparison September 2026
Perrigo Company plc (NYSE: PRGO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRGO stands at 2B. In comparison, RDHL has a market cap of 2.1M. Regarding current trading prices, PRGO is priced at $14.48 on the NYSE, while RDHL trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRGO currently has a P/E ratio of 5.80, whereas RDHL's P/E ratio is 0.13. In terms of profitability, PRGO's ROE is -0.56%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, PRGO is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for PRGO.Check RDHL's competition here